Prostate Cancer

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

Raoul S. Concepcion, MD, FACS, director of Advanced Therapeutics at Urology Associates, PC, discusses healthcare's movement away from fee-for-service reimbursements.

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.

The PARP inhibitor olaparib had an overall response rate of nearly 90% in a biomarker-defined subgroup of patients with metastatic castration-resistant prostate cancer who had DNA-repair defects.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Oliver Sartor, MD, expands on the impact of the STAMPEDE and CHAARTED trials and discusses how the results may change the treatment paradigm for prostate cancer going forward.

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer.

The additon of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial.

For those who think that men can’t die of prostate cancer, they can spend the day with me in clinic and meet some of the bravest men on the planet who are in the fight of their lives and are unfortunately afflicted with advanced metastatic prostate cancer.

The FDA has issued a de novo clearance for a minimally invasive high-intensity focused ultrasound for prostate tissue ablation called Sonablate 450 and marketed by SonaCare Medical, LLC.

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.

An updated analysis of the STAMPEDE trial upholds the survival benefit observed with early use of docetaxel in advanced prostate cancer, but does not support the introduction of zoledronic acid.

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.

Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naïve metastatic castration-resistant prostate cancer.

With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for $410 million, with additional milestone and royalty payments of up to $160 million.

Joseph F. Renzulli, II, MD, FACS, assistant professor of surgery (urology) clinical, Alpert Medical School, discusses the expanded access program in the United States for radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.